# US 2021/0340625 A1 · tRNA-DERIVED FRAGMENTS AS BIOMARKERS FOR PARKINSON'S DISEASE

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340625 A1
- Document ID: US20210340625A1
- Status: Published application
- Kind: A1
- Application number: 17/283,941
- Filed: 2019-10-10
- Published: 2021-11-04
- Earliest claimed: 2018-10-10
- Applicants: Thomas Jefferson University
- Inventors: Isidore Rigoutsos; Rogan MAGEE; Eric LONDIN
- Web page: https://patentgrep.com/patent/US20210340625A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention includes a method for analyzing tRNA-derived fragments. In one aspect, the present invention includes a method of identifying a subject in need of therapeutic intervention to treat a disease or condition, disease recurrence, or disease progression comprising characterizing the identity of tRNA fragments. The invention also includes diagnosing, identifying or monitoring a disease or condition, and a method for identifying tRNA fragments. The invention also includes diagnosing, identifying or monitoring Parkinson's disease in a subject in need thereof by characterizing the identity of tRNA fragments.

## Claims

### Claim 1

A method of identifying a subject in need of therapeutic intervention to treat a disease, condition, disease recurrence, or disease progression, the method comprising:
isolating fragments derived from tRNAs (tRFs) from a sample obtained from the subject; and
characterizing the tRFs and their relative abundance in the sample to identify a signature, wherein when the signature is indicative of a diagnosis of the disease, a treatment of the subject is recommended.

### Claim 2 (depends on 1)

The method of claim 1, wherein the tRFs are selected from the group consisting of 3′-tRFs, 3′-tRHs, 5′-tRFs, 5′-tRHs, and i-tRFs from a mitochondrion (MT).

### Claim 3 (depends on 1)

The method of claim 1, wherein the tRFs are selected from the group consisting of 3′-tRFs, 3′-tRHs, 5′-tRFs, 5′-tRHs, and i-tRFs a nucleus (Nuc).

### Claim 4 (depends on 1)

The method of claim 1, wherein the sample is isolated from a cell, a tissue, an extracellular vesicle, or a body fluid obtained from the subject.

### Claim 5 (depends on 4)

The method of claim 4, wherein the body fluid, the extracellular vesicle, the tissue or the cell is selected from the group consisting of bile, blood serum, plasma, cerebrospinal fluid, and prefrontal cortex.

### Claim 6 (depends on 1)

The method of claim 1, wherein isolating the tRFs comprises isolating tRFs fragments with a length in the range of about 10 nucleotides to about 70 nucleotides.

### Claim 7 (depends on 1)

The method of claim 1, wherein the signature comprises at least one sequence selected from the group consisting of SEQ ID NO:53135-SEQ ID NO: 63850.

### Claim 8 (depends on 1)

The method of claim 1, wherein characterizing the tRFs comprises at least one assessment selected from the group consisting of sequencing the tRFs, measuring overall abundance of a tRF mapped to the genome, measuring a relative abundance of a tRF to a reference, assessing a length of a tRF, identifying starting and ending points of a tRF, identifying a genomic origin of a tRF, and identifying a terminal modification of a tRF.

### Claim 9 (depends on 1)

The method of claim 1, wherein the tRFs and their relative abundance vary between the normal state as compared to disease state or condition.

### Claim 10 (depends on 1)

The method of claim 1, wherein the tRFs and their relative abundance vary depending on sex of the subject.

### Claim 11 (depends on 1)

The method of claim 1, wherein the disease or condition, disease recurrence, or disease progression is a brain disease.

### Claim 12 (depends on 11)

The method of claim 11, wherein the brain disease is genetically predisposed.

### Claim 13 (depends on 11)

The method of claim 11, wherein the brain disease is Parkinson's Disease.

### Claim 14

A method of diagnosing, identifying or monitoring Parkinson's Disease (PD) in a subject in need thereof, the method comprising:
isolating tRFs from a cell obtained from the subject; quantifying the tRFs using a panel of oligonucleotides engineered to detect tRFs, or another method; analyzing levels of the tRFs present in the cell; wherein a differential in the level of measured tRFs as compared to a reference is indicative of a diagnosis or identification of PD in the subject; and
providing a treatment regimen to the subject dependent on the differential in the level of measured tRFs as compared to the reference.

### Claim 15 (depends on 14)

The method of claim 14, wherein the tRFs comprise at least one sequence selected from the group consisting of SEQ ID NO:53135-SEQ ID NO: 63850.

### Claim 16

A method of identifying a subject at risk for developing Parkinson's Disease (PD) or in need of therapeutic intervention to treat Parkinson's disease (PD), the method comprising:
isolating fragments of tRFs from a sample obtained from the subject; quantifying the tRFs using a panel of oligonucleotides engineered to detect tRFs, or another method; and
characterizing the tRFs and their relative abundance in the sample to identify a signature, wherein when the signature is indicative of a prognosis for developing PD or a diagnosis for PD, a treatment of the subject is recommended.

### Claim 17 (depends on 16)

The method of claim 16, wherein the sample is isolated from a cell, tissue, extracellular vesicle, or body fluid obtained from the subject.

### Claim 18 (depends on 16)

The method of claim 16, wherein the cell, extracellular vesicle, the tissue or the body fluid is selected from the group consisting of bile, blood serum, plasma, cerebrospinal fluid, and prefrontal cortex.

### Claim 19 (depends on 16)

The method of claim 16, wherein isolating the tRFs comprises isolating tRFs with a length in the range of about 10 nucleotides to about 70 nucleotides.

### Claim 20 (depends on 16)

The method of claim 16, wherein the signature comprises at least one sequence selected from the group consisting of SEQ ID NO:53135-SEQ ID NO: 63850.

### Claim 21 (depends on 16)

The method of claim 16, wherein characterizing the tRFs comprises at least one assessment selected from the group consisting of sequencing tRFs, measuring overall abundance of a tRF mapped to the genome, measuring a relative abundance of a tRF to a reference, assessing a length of a tRF, identifying starting and ending points of a tRF, identifying genomic origin of a tRF, and identifying a terminal modification of a tRF.

### Claim 22 (depends on 16)

The method of claim 16, wherein the tRFs and their relative abundance vary between the normal state subject as compared to a subject at a risk of or suffering from PD.

### Claim 23 (depends on 16)

The method of claim 16, wherein the tRFs and their relative abundance compared to control subjects differ between subjects suffering from PD with dementia and subjects suffering from PD without dementia.

### Claim 24 (depends on 16)

The method of claim 16, wherein the tRFs and their relative abundance vary with the sex of the subject.

### Claim 25 (depends on 16)

The method of claim 16, wherein the tRFs and their relative abundance vary with the body fluid, extracellular vesicle, cell or tissue sample.

### Claim 26 (depends on 16)

The method of claim 16, wherein the tRFs and their relative abundance vary in the prefrontal cortex samples from the normal state subjects, the subjects suffering from PD with dementia, and the subjects suffering from PD without dementia.

### Claim 27 (depends on 16)

The method of claim 16, wherein the tRFs and their relative abundance vary in the cerebrospinal fluid samples from the normal state subjects, the subjects suffering from PD with dementia, and the subjects suffering from PD without dementia.

### Claim 28 (depends on 16)

The method of claim 16, wherein the tRFs and their relative abundance vary in the serum samples from the normal state subjects, the subjects suffering from PD with dementia, and the subjects suffering from PD without dementia.

### Claim 29 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 30

A kit for high-throughput analysis of tRFs fragments in a sample from a subject in need thereof, the kit comprising a collection of specially-designed qPCR assays for quantitating tRFs, or a panel of engineered oligonucleotides capable of hybridizing tRFs, or another quantification method.
